| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA624444 | A | CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg | Canis lupus familiaris | 2 | organism-based format | Scientific Literature | ||
| 2. | ALA623175 | A | Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined | Canis lupus familiaris | 1 | organism-based format | Scientific Literature | ||
| 3. | ALA624237 | A | Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg | Canis lupus familiaris | 2 | organism-based format | Scientific Literature | ||
| 4. | ALA624301 | A | Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg | Canis lupus familiaris | 2 | organism-based format | Scientific Literature | ||
| 5. | ALA623519 | A | CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 6. | ALA618537 | A | Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 7. | ALA626924 | A | Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 8. | ALA624101 | A | Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration | Rattus norvegicus | 1 | organism-based format | Scientific Literature | ||
| 9. | ALA630086 | P | Partition coefficient (logP) | 3 | small-molecule physicochemical format | Scientific Literature | |||
| 10. | ALA632908 | P | Solubility at pH 7.4 | 4 | small-molecule physicochemical format | Scientific Literature | |||
| 11. | ALA632910 | P | Solubility atpH 5.2 | 1 | small-molecule physicochemical format | Scientific Literature | |||
| 12. | ALA690868 | F | Inhibition of HUVEC cell proliferation | Homo sapiens | 8 | cell-based format | Scientific Literature | ||
| 13. | ALA766143 | B | Compound tested for ability to bind to human plasma protein | Homo sapiens | 4 | cell-free format | Scientific Literature | ||
| 14. | ALA818933 | B | Inhibition of vascular endothelial growth factor receptor 2 | Homo sapiens | 11 | single protein format | Scientific Literature | ||
| 15. | ALA820226 | F | Selectivity for VEGF-receptor 2 (KDR) over FGF-receptor 1 | 4 | assay format | Scientific Literature | |||
| 16. | ALA844101 | F | Selectivity for VEGF-receptor 2 (KDR) over FGF-receptor 2 | 4 | assay format | Scientific Literature | |||
| 17. | ALA845303 | F | Selectivity for VEGF-receptor 2 (KDR) over VEGF-receptor 1 (Flt-1) | 4 | assay format | Scientific Literature | |||
| 18. | ALA845304 | F | Selectivity for VEGF-receptor 2 (KDR) over VEGF-receptor 3 (Flt-4) | 4 | assay format | Scientific Literature | |||
| 19. | ALA845305 | F | Selectivity for VEGF-receptor 2 (KDR) over PDGF-receptor beta | 4 | assay format | Scientific Literature | |||
| 20. | ALA845306 | F | Selectivity for VEGF-receptor 2 (KDR) over c-Src | 4 | assay format | Scientific Literature |
The page will load shortly, Thanks for your patience!